Physician profile
Bert Maurice Morrow
NPI 1831136977
$3,661.83
in general payments reported to CMS, 2019-2025
30 companies · $35.06 in 2025
The $35.06 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $328 · 2021: $618 · 2022: $858 · 2023: $830 · 2024: $324 · 2025: $35.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.77 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $767.06 | 2019-2024 | Myrbetriq |
| Sumitomo Pharma America, INC. | $332.91 | 2023-2024 | Orgovyx, Gemtesa |
| Pfizer INC. | $312.53 | 2019-2024 | |
| Boston Scientific Corporation | $262.08 | 2019-2024 | Spaceoar Vue System - 10ml |
| Myovant Sciences INC. | $257.24 | 2021-2022 | |
| Neotract INC. | $187.29 | 2019-2020 | |
| Abbvie INC. | $167.50 | 2022-2024 | |
| Allergan, INC. | $154.24 | 2019-2022 | |
| Teleflex LLC | $131.68 | 2021-2023 | Urolift |
| Coloplast Corp | $121.15 | 2020-2023 | Speedicath |
| Antares Pharma, INC. | $113.24 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Endo Pharmaceuticals INC. | $98.87 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $96.71 | 2023-2024 | Prolaris |
| Ferring Pharmaceuticals INC. | $86.78 | 2019-2024 | Adstiladrin |
| Urovant Sciences INC | $73.14 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $72.98 | 2023-2024 | |
| Zyla Life Sciences, INC. | $70.71 | 2019-2020 | |
| Blue Earth Diagnostics | $49.79 | 2019-2021 | |
| Janssen Biotech, INC. | $36.64 | 2022-2023 | Erleada |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Axonics, INC. | $33.78 | 2020-2023 | Axonics |
| Verity Pharmaceuticals INC. | $30.65 | 2024 | Trelstar |
| 180 Medical, INC. | $26.94 | 2019 | |
| Accord Healthcare, INC. | $25.43 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $23.12 | 2022 | |
| Halozyme INC | $22.81 | 2023 | |
| Aytu Biopharma, INC. | $22.28 | 2019 | |
| Rochester Medical Corporation | $21.07 | 2021 | |
| Smith+Nephew, INC. | $17.13 | 2024 | Stravix Pl |
| Clarus Therapeutics INC. | $11.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bert Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.